Clinical trials: Zoledronic acid
Non-Small Cell Lung Cancer
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.
- Trial name
- NCT01951586
- Testing
- Denosumab, Zoledronic acid, Standard Chemotherapy
- Where
- 74 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Amgen
Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.
- Conditions
- Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung, Metastases
- Trial name
- NCT00265200
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Louisville
Breast Cancer, Osteoporosis
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00107263
- Testing
- letrozole, zoledronic acid
- Volunteers
- 558 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chemotherapy, Breast Cancer, Metastatic
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
Low-dose metronomic(LDM)chemotherapy as well as anti-inflammatory agents and bisphosphonates have shown anti-angiogenic properties on tumor vasculature.
- Trial name
- NCT01067989
- Testing
- Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- HaEmek Medical Center, Israel
Multiple Myeloma and Plasma Cell Neoplasm
Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
RATIONALE: Paricalcitol may cause multiple myeloma cells to look more like normal cells, and to grow and spread more slowly. Paricalcitol may also stop the growth of the cancer cells by blocking blood flow to the cancer.
- Trial name
- NCT00258258
- Testing
- paricalcitol, zoledronic acid
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Osteoporosis
Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid
1. The study will assess the safety and tolerability of a single-infusion of zoledronic acid 5 mg administered in a private medical practice setting by a nurse provided by a nationwide infusion service.
- Trial name
- LISA (NCT00745485)
- Testing
- zoledronic acid
- Where
- 14 sites in Australia
- Volunteers
- 186 people
- Sponsor
- Novartis Pharmaceuticals
Postmenopausal Osteoporosis, Postmenopausal Osteopenia
The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
This study is a prospective, multicenter, open-label, randomized non-inferiority trial comparing intravenous ibandronate and zoledronic acid as sequential therapy after denosumab discontinuation in postmenopausal women with…
- Conditions
- Postmenopausal Osteoporosis, Postmenopausal Osteopenia, Primary Osteoporosis, Osteoporosis
- Trial name
- NCT07406685
- Testing
- Ibandronate IV, Zoledronic acid IV
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- National Taiwan University Hospital
Multiple Myeloma
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
Assessment of the antitumour effect of zoledronic acid in patients with multiple myeloma and asymptomatic biochemical relapse It´s proposed to investigate the use of Zoledronic acid as single therapy in patients with Multiple…
- Trial name
- AZABACHE (NCT01087008)
- Testing
- zoledronic acid, No treatment control
- Where
- 16 sites in Spain
- Volunteers
- 103 people
- Sponsor
- PETHEMA Foundation
Bone Density, Pain
Bisphosphonate Therapy in MONA Spectrum Disorder
Multicentric osteolysis, nodulosis and arthropathy (MONA) spectrum disorder is a rare inherited progressive skeletal disorder caused by mutations in the matrix metalloproteinase 2 (MMP2) gene. Treatment options are limited.
- Conditions
- Bone Density, Pain, Fracture
- Trial name
- NCT02823925
- Testing
- Pamidronate or Zoledronate
- Volunteers
- 3 people
- Sponsor
- Medical University Innsbruck
Pre-integration Failure of Dental Implant
Initial Fixation of Bisphosphonate-coated Dental Implants
16 patients will be included. Each patient receives 2 dental implants. One of them is coated with a drug, zoledronate, to improve fixation.
- Trial name
- NCT02044978
- Testing
- Zoledronate-coated dental implant
- Where
- 2 sites in Sweden
- Volunteers
- 16 people
- Sponsor
- Per Aspenberg
Osteoporosis
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
This study was designed to evaluate the efficacy and safety of zoledronic acid compared to placebo in osteoporotic children treated with glucocorticoids
- Trial name
- NCT00799266
- Testing
- Zoledronic acid
- Where
- 12 sites in Australia, Canada and 4 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Metastatic Cancer
Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: A positron emission tomography scan is a procedure in which a small amount of radioactive sugar is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where…
- Trial name
- NCT00559897
- Testing
- 3'-deoxy-3'-[18F]FLT, Single photon emission computed tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Renal Osteodystrophy
Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation
The purpose of this study is to determine whether zolendronic acid, a third generation bisphosphonate, is effective in preventing bone loss in the first year after kidney transplantation.
- Trial name
- NCT01675089
- Testing
- Zoledronic acid
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- University of Sao Paulo General Hospital
Metastatic Cancer, Prostate Cancer
Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen blockade therapy may lessen the amount of androgens made by the body. Zoledronic acid may help relieve some of the symptoms caused by bone metastasis.
- Trial name
- ZAPCA (NCT00685646)
- Testing
- antiandrogen therapy, zoledronic acid
- Where
- Japan
- Volunteers
- 227 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Atypical Femoral Fractures, Osteoporosis
Exome Sequencing for Atypical Femoral Fractures
The purpose of this study is to determine whether women who have atypical subtrochanteric and diaphyseal femoral fractures after treatment with bisphosphonates for osteoporosis, have a genetic predisposition to these unusual…
- Conditions
- Atypical Femoral Fractures, Osteoporosis, Bisphosphonate Therapy
- Trial name
- NCT02731040
- Testing
- Bisphosphonate
- Volunteers
- 38 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Osteoporosis
Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00114270
- Testing
- letrozole, zoledronic acid
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Virginia
Osteogenesis Imperfecta
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
Osteogenesis imperfecta (OI) is an inherited disease of the connective tissue. Symptoms are fractures, growth retardation, blue sclera, bad teeth, impaired hearing a.o.
- Trial name
- NCT01679080
- Testing
- Zoledronic acid, Teriparatide, No active treatment
- Where
- 3 sites in Denmark
- Volunteers
- 9 people
- Sponsor
- University of Aarhus
Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.
- Conditions
- Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
- Trial name
- Asteroid (NCT03118570)
- Testing
- setrusumab, Calcium, Vitamin D
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 112 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Traumatic Brain Injury, Spinal Cord Injuries
Continuous Passive Motion Versus Heterotopic Ossification
The investigators hypothesize that Heterotopic Ossification (HO) formation can be suppressed if the application of a Continuous Passive Motion (CPM) device can be performed for a substantial amount of time.
- Conditions
- Traumatic Brain Injury, Spinal Cord Injuries, Stroke
- Trial name
- CPMversusHO (NCT05906056)
- Testing
- Continuous Passive Motion (CPM), Conventional physiotherapy (PT), Zoledronic Acid Injection
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- University of Ioannina
Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
CHronic Nonbacterial Osteomyelitis International Registry
The objective of the study is to establish a prospective disease registry for chronic recurrent multifocal osteomyelitis (CRMO)/chronic nonbacterial osteomyelitis (CNO) in order to investigate the natural history of the disease…
- Trial name
- CHOIR (NCT04725422)
- Testing
- Methotrexate, Sulfasalazine, Leflunomide
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Seattle Children's Hospital